Salute, Brescianini (Amgen Italia): "La piattaforma BiTE unisce in modo inedito biologia e tecnologia"

adnkronos

(Adnkronos) - “Nello sviluppo della piattaforma BiTE Amgen ha avuto un approccio estremamente innovativo, basato sulla connessione inedita tra la biologia e la tecnologia. Si è partiti dalla leucemia linfoblastica acuta in fase di recidiva refrattaria e si è poi avanzati verso fasi più precoci della malattia, passando attraverso la cosiddetta malattia minima residua fino ad arrivare allo sviluppo in prima linea. Tutto questo è stato possibile grazie all’approccio innovativo di Amgen, ma anche grazie al fondamentale e determinante contributo della comunità ematologica internazionale e, in particolare, di quella italiana”. Così Alessandra Brescianini, direttore medico di Amgen Italia, a margine dell’evento con il quale Amgen ha illustrato i risultati dello studio clinico di Fase III E1910, che dimostrano come l'introduzione dell’anticorpo bispecifico blinatumomab nella prima linea di trattamento aumenti significativamente la sopravvivenza globale dei pazienti affetti da leucemia linfoblastica acuta (Lla) da linfociti B Ph- di nuova diagnosi.

Transcript

00:00The platform is called BITE, Bite Specific T-Cell Engager, and it is an extremely innovative platform,

00:11characterized by the possibility of creating a link between the toxic tissue lymphocyte,

00:18the CD3, and the tumor cell, which in the case of Vinatumumab is the CD19,

00:24expressed on the surface of the tumor cell, the acute lymphoblastic leukemia lymphoblast.

00:30Thanks to this link, the potential toxic tissue of the T lymphocyte is activated,

00:36which creates an opening within the tumor cell and releases enzymes that induce the apoptosis of the tumor cell.

00:45This apoptosis is a serial apoptosis, a serial lysis, therefore continuous, of the tumor cell,

00:52and at the same time there is also a proliferation of the toxic tissue lymphocytes,

00:57so basically the weapon against the tumor cell multiplies and induces this serial lysis of the tumor cell.

01:05Amgen, in the development of this platform, had an extremely innovative approach,

01:10based on the unprecedented connection between biology and technology.

01:16It started, of course, from acute lymphoblastic leukemia, in the recidivism phase,

01:24and then advanced towards the earlier phases of the disease,

01:30passing through the so-called minimal residue disease, that is, leukemic clones present in minimal quantity,

01:36but which inevitably lead to the clinical and hematological relapse of the patient,

01:43up to the early development.

01:46All this was possible thanks to Amgen's innovative approach,

01:50but also thanks to the fundamental and decisive contribution of the international hematological community,

01:57and in particular of the Italian hematological community,

02:00whose contribution has allowed us to reach these goals in the development of the drug.

Category

Transcript

Comments

Recommended